Fairvalue-Calculator Fairvalue-Calculator
EN DE

Photocure ASA (PHCUF) Fair Value & Analysis

Healthcare · US · Market cap $179M

Price$6.18
Fair Value$5.90
Upside-4.5%
Quality95/100
Evidence: Medium Range $4.25 – $9.95

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Photocure ASA (PHCUF) currently trades at $6.18, while our model-based Fair Value estimate is $5.90 — implying the stock looks roughly 4.5% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).

About the company

Photocure ASA, together with its subsidiaries, engages in the research, development, production, distribution, marketing, and sale of pharmaceutical products. It operates through two segments, Commercial Franchise and Development Portfolio. The company offers Hexvix/Cysview for the detection and management of bladder cancer. It is also developing Cevira, a photodynamic drug-device combination product candidate for the non-surgical treatment of high-grade cervical dysplasia. The company has a license agreement with Asieris MediTech Co to develop and commercialize Cevira; and a strategic agreement with Richard Wolf GmbH to develop and commercialize a 4K LED high-definition reusable blue light cystoscope based on Richard Wolf's System blue technology. It sells its products to pharmaceutical wholesalers, pharmacies, and hospitals through license partners. The company operates in the Nordic countries, Germany, France, Austria, the United Kingdom, the Benelux, Italy, other European countr…

Open the full interactive analysis →

Similar stocks

Takeda Pharmaceutical Company (TAKP34) +885% Jiangsu Hengrui Pharmaceuticals Co (600276) -44% Sun Pharmaceutical Industries Limited (SUNPHARMA) -49% Zoetis Inc (Z1TS34) -75% Hansoh Pharmaceutical Group (3692) -18% Divi's Laboratories Limited (DIVISLAB) -78%

Frequently asked questions

Is Photocure ASA (PHCUF) undervalued?
As of Jun 24, 2026, our model estimates a fair value of $5.90 versus a price of $6.18 — about −5% (overvalued). Model-based estimate, not financial advice.
What is the fair value of PHCUF?
Our 21-model fair value for Photocure ASA is $5.90 (as of Jun 24, 2026), built from audited fundamentals. The current price is $6.18.
What is the quality score of PHCUF?
Photocure ASA has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.